Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT00068003 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Harvesting Cells for Experimental Cancer Treatments

StatusEnrolling by Invitation
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Amendment history

The 50 most recent of 502 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. Minor

    Re-verified, no change to tracked fields

  2. Notable

    Primary endpoints: details revised at 1 of 3 entries

    Eligibility criteria expanded, about 32 words; Study description revised; Publications: details revised at 6 of 6 entries

    Show what changed: Eligibility criteria
    * ELIGIBILITY CRITERIA FOR PATIENTS WITH A CURRENT DIAGNOSIS OF CANCER: INCLUSION CRITERIA: * Patients must have a form of cancer currently being studied in the NCI-SB. * Patient is able to understand and willing to sign a written informed consent document. * Age greater than or equal to 18 years. * Clinical performance status of ECOG 0 or 1. * Serology * Seronegative for HIV antibody. (The experimental treatments [...] rimental treatment and more susceptible to its toxicities). * Seronegative for hepatitis B surface antigen and seronegativ [...] the presence of antigen by RT-PCR and be HCV RNA negative. [...]
    Show what changed: Study description
    [...] gnosis of cancer. Eligibility: Patients with cancer must be \>= 18 years of age and meet the laboratory safety testing fo [...]

  3. Minor

    48 amendments

    48 re-verifications since 2024-10-12, no change to tracked fields

    v453-v500

  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
National Cancer Institute (NCI)
961 trials monitored
See 68 trials at risk
Breast Cancer
5,213 trials monitored
See 275 trials at risk
Lung Cancer
4,057 trials monitored
See 218 trials at risk
Non-Small Cell Lung Cancer (NSCLC)
2,932 trials monitored
See 159 trials at risk
and 1 more disease
Background: The NCI Surgery Branch has developed experimental therapies that involve taking white blood cells from patients' tumor or from their blood, growing them in the laboratory in large numbers, and then giving the cells back to the patient. Objective: This study will collect white blood cells from normal volunteers and white blood cells and/or tumor cells, from patients who have been screened for and are eligible for a NCI Surgery Branch treatment protocol. The cells collected from normal volunteers will be used as growth factors for the cells during the period of laboratory growth. The cells and/or tumor from patients will be used to make the cell treatment product. Eligibility: Patients must be eligible for a NCI Surgery Branch Treatment Protocol Normal Volunteers must meet the criteria for blood donation Design Both patients and normal Volunteers will undergo apheresis. Patients will then undergo further testing as required by the treatment protocol. There is no required follow up for normal volunteers.
Trial Details
NCT Number NCT00068003
Lead Sponsor National Cancer Institute (NCI)
Conditions Melanoma, Gastrointestinal Cancer, Metastatic Cancer, Breast Cancer, Non-Small Cell Lung Cancer
Enrollment 7,000 participants
Start Date
Updated on ClinicalTrials.gov